Analysts think MNMD stock price could increase by 202%
Feb 26, 2025, 12:25 PM
-2.52%
What does MNMD do
Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company based in New York, focused on developing novel treatments for brain health disorders, including MM-120 for anxiety and ADHD, and MM-402 for autism. Founded in 2015, the company employs 57 people and targets neurotransmitter pathways using psychedelics and empathogens.
11 analysts think MNMD stock price will increase by 202.22%. The current median analyst target is $20.40 compared to a current stock price of $6.75. The lowest analysts target is $16.16 and the highest analyst target is $57.75.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
